



Spinal Cord Injury: From Mechanisms to Nanotherapeutic Approaches

Guest Editor:

Dr. Pietro Veglianesi

Dipartimento di Neuroscienze,
Istituto di
Ricerche Farmacologiche “Mario
Negri”, via La Masa 19, 20156
Milano, Italy

Deadline for manuscript
submissions:

closed (31 March 2023)

Message from the Guest Editor

Dear Colleagues,

Spinal cord injury (SCI) remains the most relevant degenerative condition of the spinal cord, and the secondary injury, following the primary trauma, is the most therapeutic target. Advancement in nanomaterials as potential therapeutic solutions for medical application has been demonstrated to be promising for SCI. Many studies have applied nanostructured material to support cell therapy or deliver compounds in a selective way in single cells after SCI. Although these approaches are widely used in SCI, the real potential effect has not been fully elucidated. This Special Issue aims to focus on the application of the more innovative biomaterials and will provide an overview of new nanostructure-based therapeutic approaches that are able to treat secondary injury after trauma.

Dr. Pietro Veglianesi

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)